What were your top takeaways in Myositis from ACR Convergence 2025?

ACR Convergence had an outstanding selection of myositis offerings, and the number of people attending the sessions reflects the increasing recognition of these heterogeneous diseases, coupled with the frequency that non-myositis specialist clinicians will encounter these entities. The convention pr...

CD-19 CAR-T was highly successful in Myositis and put many patients in remission without ongoing immunosuppression. Also, FcRN receptor blockers phase 2 was positive in Myositis, and there is an ongoing Phase 3 trial going on. Positive Phase 3 with Brepocitinib (JAK1/TYK2 inhibitor) that will likely...